Browse > Article
http://dx.doi.org/10.4070/kcj.2012.42.3.164

Prognostic Impact of Baseline High-Sensitivity C-Reactive Protein in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Based on Body Mass Index  

Ahmed, Khurshid (Department of Cardiovascular Medicine, Chonnam National University College of Medicine)
Jeong, Myung-Ho (Department of Cardiovascular Medicine, Chonnam National University College of Medicine)
Chakraborty, Rabin (Department of Cardiology, Apollo Gleneagles Hospital)
Cho, Kyung-Hoon (Department of Cardiovascular Medicine, Chonnam National University College of Medicine)
Sim, Doo-Sun (Department of Cardiovascular Medicine, Chonnam National University College of Medicine)
Hong, Young-Joon (Department of Cardiovascular Medicine, Chonnam National University College of Medicine)
Ahn, Young-Keun (Department of Cardiovascular Medicine, Chonnam National University College of Medicine)
Hachinohe, Daisuke (Department of Cardiovascular Medicine, Chonnam National University College of Medicine)
Cho, Myeong-Chan (Department of Cardiology, Chungbuk National University College of Medicine)
Kim, Chong-Jin (Department of Cardiovascular Medicine, Kyunghee University College of Medicine)
Kim, Young-Jo (Department of Cardiology, Yeungnam University College of Medicine)
Publication Information
Korean Circulation Journal / v.42, no.3, 2012 , pp. 164-172 More about this Journal
Abstract
Background and Objectives: Serum high sensitivity C-reactive protein (hs-CRP) is a marker of inflammation and may lead to the development of atherosclerosis, adversely affecting mortality. The aim of this study was to evaluate the relationship between baseline hs-CRP level and 12-month clinical outcomes in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) according to their body mass index (BMI) status. Subjects and Methods: Using data from the Korea Acute Myocardial Infarction Registry from November 2005 to September 2008, a total of 8174 consecutive AMI patients were studied. Cox proportional hazard model revealed that higher baseline levels of hs-CRP was associated with 12-month all-cause mortality (p=0.045). To further understand this association, patients were divided into 3 groups based on their body mass index: 1) overweight/obese, 2) normal weight, and 3) underweight patients. Then each group was stratified into quartiles based on their hs-CRP. Results: In overweight/obese patients, Cox model showed significant association of hs-CRP with 12-month mortality when adjusted for age and gender (p<0.001), however, after adjustment with multiple covariates, mortality was highest in the 4th quartile {HR 2.382, (1.079-5.259), p=0.032} though statistically insignificant (p=0.172). We observed no significant association of serum hs-CRP with 12-month mortality in normal weight (p=0.681) and underweight (p=0.760) patients. Conclusion: Higher baseline hs-CRP level (${\geq}$4.08 mg/dL) in overweight/obese AMI patients showed significant association with 12-month all-cause mortality independent of other prognostic markers.
Keywords
C-reactive protein; Overweight; Obesity; Body mass index; Myocardial infarction;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem 2008;54:335-42.   DOI   ScienceOn
2 Marsik C, Kazemi-Shirazi L, Schickbauer T, et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem 2008; 54:343-9.   DOI   ScienceOn
3 Kang WY, Jeong MH, Ahn YK, et al. Obesity paradox in Korean patients undergoing primary percutaneous coronary intervention in STsegment elevation myocardial infarction. J Cardiol 2010;55:84-91.   DOI   ScienceOn
4 Devaraj S, O'Keefe G, Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab 2005;90:4549-54.   DOI   ScienceOn
5 Noh HJ, Kwon NH, Joo SB. Severity of coronary atherosclerosis; influence of mtabolic syndrome risk factor clustering and hs-CRP. Korean Circ J 2006;36:802-8.
6 Sim DS, Jeong MH, Kang JC. Current management of acute myocardial infarction: experience from the Korea Acute Myocardial Infarction Registry. J Cardiol 2010;56:1-7.   DOI   ScienceOn
7 Lee KH, Jeong MH, Ahn YK. Sex differences of the clinical characteristics and early management in the Korea Acute Myocardial Infarction Registry. Korean Circulation J 2007;37:64-71.   DOI   ScienceOn
8 Sim DS, Kim JH, Jeong MH. Differences in clinical outcomes between patients with ST-elevation versus non-ST-elevation acute myocardial infarction in Korea. Korean Circ J 2009;39:297-303.   DOI   ScienceOn
9 WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.   DOI   ScienceOn
10 Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 2002;144:981-6.   DOI   ScienceOn
11 Kini AS. Coronary angiography, lesion classification and severity assessment. Cardiol Clin 2006;24:153-62, v.   DOI   ScienceOn
12 Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.   DOI   ScienceOn
13 Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-7.   DOI   ScienceOn
14 Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.   DOI   ScienceOn
15 Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.   DOI   ScienceOn
16 Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels: is adipocyte size associated with inflammation in adults? J Endocrinol Invest 2007;30:210-4.   DOI
17 Bastard JP, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002;87:2084-9.   DOI   ScienceOn
18 Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003;311:372-9.   DOI   ScienceOn
19 Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin- 6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.   DOI   ScienceOn
20 Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107:1783-90.   DOI   ScienceOn
21 Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282:2131-5.   DOI   ScienceOn
22 Araujo JP, Lourenco P, Azevedo A, et al. Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 2009;15:256-66.   DOI   ScienceOn
23 De Sutter J, de Buyzere M, Gheeraert P, et al. Fibrinogen and C-reactive protein on admission as markers of final infarct size after primary angioplasty for acute myocardial infarction. Atherosclerosis 2001;157: 189-96.   DOI   ScienceOn
24 Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003;167:73-9.   DOI   ScienceOn
25 Ryu SY, Lee YS, Park J, Kang MG, Kim KS. Relations of plasma highsensitivity C-reactive protein to various cardiovascular risk factors. J Korean Med Sci 2005;20:379-83.   DOI   ScienceOn
26 Bursi F, Weston SA, Killian JM, Gabriel SE, Jacobsen SJ, Roger VL. C-reactive protein and heart failure after myocardial infarction in the community. Am J Med 2007;120:616-22.   DOI   ScienceOn
27 Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002;4:331-6.   DOI   ScienceOn
28 Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 2001;37:1284-8.   DOI   ScienceOn
29 Tataru MC, Heinrich J, Junker R, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000;21:1000-8.   DOI   ScienceOn
30 Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.   DOI   ScienceOn
31 Rao AD, Milbrandt EB. To JUPITER and beyond: statins, inflammation, and primary prevention. Crit Care 2010;14:310.   DOI
32 De Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982;47:239-43.   DOI   ScienceOn
33 Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58   DOI   ScienceOn